Viatris's average Accounts Receivable for the
three
months ended in Jun. 2024 was $2,737 Mil. Viatris's Revenue for the
three
months ended in Jun. 2024 was $3,797 Mil.
Hence, Viatris's Days Sales Outstanding for the
three
months ended in Jun. 2024 was 65.79.
The historical rank and industry rank for Viatris's Days Sales Outstanding or its related term are showing as below:
VTRS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.19 Med: 89.5 Max: 99.78
Current: 70.19
During the past 13 years, Viatris's highest Days Sales Outstanding was 99.78. The lowest was 70.19. And the median was 89.50.
VTRS's Days Sales Outstanding is ranked better than 51.7% of 969
companies
in the Drug Manufacturers industry
Industry Median: 71.7
vs VTRS: 70.19
Viatris's Days Sales Outstanding
declined
from Jun. 2023 (71.55) to Jun. 2024 (65.79).
Viatris Days Sales Outstanding Historical Data
The historical data trend for Viatris's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viatris's Days Sales Outstanding
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris's Days Sales Outstanding Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Viatris's Days Sales Outstanding falls into.
Viatris Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (NAS:VTRS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Viatris Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Viatris's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your 